Dr Brett Hollier
Position:
- Research Fellow, Australian Prostate Cancer Research Centre-Queensland
- Research Fellow & Group Leader - IGF Mechanistic studies, Tissue Repair & Regeneration Program, QUT, IHBI
Biography:
Dr Hollier is an early career researcher with an emerging national and international profile for his work in Insulin/Insulin-like growth factor (IGF) biology and mechanisms of cellular migration and cancer metastasis.
In recognition of his research, Dr Hollier has been invited and presented his work at both national and international conferences as well as external research institutes. Dr Hollier was recruited to the University of Texas M.D Anderson Cancer Center (MDACC) (Houston, TX, USA) in September 2008 to further his research interests into the mechanisms of cancer metastasis and was awarded a prestigious Susan G Komen for the Cure® Foundation Postdoctoral Fellowship (USA) (2009) for his research investigating the role of the epithelial-to-mesenchymal transition (EMT) in cancer stem cells and metastasis.
Dr Hollier returned to Australia (Sep 2010) to initiate his own independent research laboratory investigating mechanisms of cancer progression at the Institute of Health and Biomedical Innovation, QUT. Dr Hollier was recently awarded a three-year Smart Futures Fellowship from the Queensland Government with a focus on improving targeted therapies to halt cancer progression. To date, Dr Hollier has been directly involved in attracting $650K in competitive grant research funding including three Postdoctoral fellowships, one ARC Linkage, one Early Career Researcher and two Pilot Study grants.
He has published 13 peer reviewed articles, including nine original data journal articles, two invited journal review articles and two book chapters, in high impact internationally recognised journals. These have included PNAS, Oncogene, Stem Cells and two articles in Endocrinology with 205 citations to date. Reflecting Dr Hollier's research interests, these publications span the fields of growth factor biology and mechanism regulating cancer metastasis. Dr Hollier has been lead author on a number of papers describing for the first time the signalling and transcriptional mechanisms via which novel complexes of growth factors and matrix proteins induce cancer progression.
Best publications:
- Thibaudeau, L, Taubenberger, AV, Holzapfel, BM, Quent, VM, Fuehrmann, T, Hesami, P, Brown, TD, Dalton, PD, Power, CA, Hollier, BG, Hutmacher, DW. (2014). A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. Disease Models & Mechanisms. In Press 2014.
- Hollier BG, Tinnirello A, Werden S, Evans K, Taube J, Sarkar T, Sphyris N, Shariati M, Kumar S, Battula V, Herschkowitz J, Guerra R, Chang J, Miura N, Rosen JM, Mani SA. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 2013 Mar 15;73(6):1981-92. doi: 10.1158/0008-5472.CAN-12-2962. Epub 2013 Feb 1. PMID: 23378344.
- Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, Hendy SC, Adomat HH, Gleave ME, Pollak M, Herington A, Nelson CC. IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer. 2013 Mar 22;20(2):173-86. doi: 10.1530/ERC-12-0250. Print 2013 Apr. PMID: 23319492.
- Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. doi: 10.1073/pnas.1004900107. Epub 2010 Aug 16. Erratum in: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19132. PMID: 20713713.
- Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):29-43. doi: 10.1007/s10911-009-9110-3. Epub 2009 Feb 26. PMID: 19242781.
Metastasis, EMT, Cancer Stem Cells, Growth factors, Extracellular matrix, CRPC.
